TickerFacts.

Company research / PFE

Pfizer Inc (PFE)

Build a valuation ↗↓ Download CSV

SEC name PFIZER INC · CIK 0000078003 · NYSE · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Pfizer Inc reported revenue of $62.58B. Revenue fell 1.6% from the prior annual period. Over the twelve months to 2026-06-28, revenue was $63.70B.

Key ratios (year ended 2025-12-31)

74.3%
Gross margin (computed)
12.4%
Net margin
9.0%
Return on year-end equity
-1.6%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-16

Headquarters locality: New York City · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-28 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-28		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$63.70B$62.58B$63.63B$59.55B$101.17B$81.29B$41.65B$40.91B$40.83B$52.55B$52.82B
Cost of Revenue$17.08B$16.07B$17.85B$24.95B$34.34B$30.82B$8.48B$8.05B$8.99B$11.23B$12.32B
Gross Profit (computed)$46.61B$46.51B$45.78B$34.60B$66.83B$50.47B$33.17B$32.85B$31.84B$41.32B$40.50B
R&D Expense$11.05B$10.44B$10.82B$10.68B$11.43B$10.36B$8.71B$8.38B$7.76B$7.68B$7.89B
Depreciation & Amortization$6.58B$6.59B$7.01B$6.29B$5.06B$5.19B$4.68B$5.75B$6.38B$6.27B$5.76B
Net Income$4.33B$7.77B$8.03B$2.12B$31.37B$21.98B$9.16B$16.03B$11.15B$21.31B$7.21B
EPS (Diluted)n/a$1.36$1.41$0.37$5.47$3.85$1.63$2.82$1.87$3.52$1.17
Total Assets$201.13B$208.16B$213.40B$226.50B$197.21B$181.48B$154.23B$167.59B$159.42B$171.80B$171.62B
Total Liabilities$115.64B$121.39B$124.90B$137.21B$101.29B$104.01B$90.76B$104.15B$95.66B$100.14B$111.78B
Long-Term Debtn/an/an/an/an/an/a$4.00Bn/an/an/a$31.40B
Shareholders' Equity$85.49B$86.78B$88.50B$89.29B$95.92B$77.46B$63.47B$63.45B$63.76B$71.66B$59.84B
Cash & Equivalents$976.00M$1.14B$1.04B$2.85B$416.00M$1.94B$1.79B$1.12B$1.14B$1.34B$2.60B
Operating Cash Flow$13.40B$11.70B$12.74B$8.70B$29.27B$32.58B$14.40B$12.59B$15.83B$16.80B$16.19B
Capital Expenditures$2.42B$2.63B$2.91B$3.91B$3.24B$2.71B$2.23B$2.05B$1.98B$1.96B$1.82B
Free Cash Flow$10.98B$9.07B$9.84B$4.79B$26.03B$29.87B$12.18B$10.54B$13.84B$14.85B$14.37B
Share Repurchasesn/an/a$0$0$2.00B$0$0$8.87B$12.20B$5.00B$5.00B
Dividends Per Sharen/a$1.72$1.69$1.65$1.61$1.57$1.53$1.46$1.38$1.30$1.22
Weighted Average Diluted Sharesn/a5.71B5.70B5.71B5.73B5.71B5.63B5.67B5.98B6.06B6.16B
EPS (Basic)n/a$1.37$1.42$0.38$5.59$3.92$1.65$2.88$1.90$3.57$1.18

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView